CROI 2025 - CROI 2025

Oral Abstract: Evolution of HIV and Mpox Epidemics

"Introduction of Speakers Part 1" by

Oral Abstract: Evolution of HIV and Mpox Epidemics

"Comparing Empirical HIV Incidence With UNAIDS Estimated Incidence Declines in Sub-Saharan Africa" by Oliver Stevens Imperial College London, London, UK

Oral Abstract: Evolution of HIV and Mpox Epidemics

"All-Cause and Cause-Specific Mortality Trends Among Persons With and Without HIV in Rural Tanzania" by Julie Ambia University of Bristol, Bristol, UK

Oral Abstract: Evolution of HIV and Mpox Epidemics

"Associations of Dolutegravir and the COVID-19 Pandemic on Viral Suppression in South African Adults" by Haroon Moolla University of Cape Town, Cape Town, South Africa

Oral Abstract: Evolution of HIV and Mpox Epidemics

"Questions and Answers Part 1" by

Oral Abstract: Evolution of HIV and Mpox Epidemics

"Introduction of Speakers Part 2" by

Oral Abstract: Evolution of HIV and Mpox Epidemics

"A Multistage Sampling Approach to Refine HIV Mortality Estimates in KwaZulu-Natal, South Africa" by Alastair VanHeerden Human Sciences Research Council, Pretoria, South Africa

Oral Abstract: Evolution of HIV and Mpox Epidemics

"Genotypic Characterization of Mpox and a Tale of 2 Co-Circulating Viruses in Uganda" by Nicholas Bbosa London School of Hygiene & Tropical Medicine, London, UK

Oral Abstract: Evolution of HIV and Mpox Epidemics

"Characterization of Mpox Cases in Uganda: Diversity of the Confirmed Cases" by Ritah Namusoosa Ministry of Health Uganda, Kampala, Uganda

Oral Abstract: Evolution of HIV and Mpox Epidemics

"Questions and Answers Part 2" by

Oral Abstract: HIV Reservoirs and Cure Strategies

"Introduction of Speakers Part 1" by

Oral Abstract: HIV Reservoirs and Cure Strategies

"5’Leader Defects in HIV Plasma Clones Drive 80% of Persistent Viremia on Long-Term ART" by Francesco R. Simonetti The Johns Hopkins University School of Medicine, Baltimore, MD, USA

Oral Abstract: HIV Reservoirs and Cure Strategies

"BACH2-Driven Tissue Resident Memory Programs Promote HIV-1 Persistence" by Yulong Wei Yale University, New Haven, CT, USA

Oral Abstract: HIV Reservoirs and Cure Strategies

"Longitudinal Co-Evolution of HIV-1 Reservoir Cells and Immune Effector Cells During Long-Term Art" by Weiwei Sun Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA

Oral Abstract: HIV Reservoirs and Cure Strategies

"AZD5582 and Venetoclax Reduce SIV Reservoirs in ART-Suppressed Macaques" by Benedicth Ukhueduan Emory University, Atlanta, GA, USA

Oral Abstract: HIV Reservoirs and Cure Strategies

"Questions and Answers Part 1" by

Oral Abstract: HIV Reservoirs and Cure Strategies

"Introduction of Speakers Part 2" by

Oral Abstract: HIV Reservoirs and Cure Strategies

"HIV GAG x CD3 Soluble TCR Bispecific Reduces the Active HIV Reservoir in a Phase I/II Trial" by Beatriz Mothe Fundació Lluita contra la SIDA, Badalona, Spain

Oral Abstract: HIV Reservoirs and Cure Strategies

"Evaluation of 2 bNAbs Plus Vesatolimod in Early-Treated South African Women With HIV-1 During ATI" by Thumbi Ndung'u Africa Health Research Institute, Mtubatuba, South Africa

Oral Abstract: HIV Reservoirs and Cure Strategies

"A Single Infusion of CCR5-/- CD4 Tscm Cells Promotes Control of SIV Upon ATI" by Ashish A. Sharma Emory University, Atlanta, GA, USA

Oral Abstract: HIV Reservoirs and Cure Strategies

"RIO: A Randomised Placebo-Controlled Study of 2 LS-bNAbs in People Treated in Early HIV" by Sarah Fidler Imperial College London, London, UK

Oral Abstract: HIV Reservoirs and Cure Strategies

"Questions and Answers Part 2" by

Oral Abstract: Maternal-Child Health and Treatment of Malignancies

"Introduction of Speakers Part 1" by

Oral Abstract: Maternal-Child Health and Treatment of Malignancies

"Maternal Tenofovir Prophylaxis With Active Immunization to Prevent Infant Hepatitis B" by Gonzague Jourdain Chiang Mai University, Chiang Mai, Thailand

Oral Abstract: Maternal-Child Health and Treatment of Malignancies

"Efficacy of Home Visits for Pregnant Couples to Promote Couple HIV Testing and Family Health" by Lynae Darbes University of Michigan, Ann Arbor, MI, USA

Oral Abstract: Maternal-Child Health and Treatment of Malignancies

"Dolutegravir Does Not Reduce Levonorgestrel or Medroxyprogesterone Acetate Concentrations in WLWH" by Rebecca Ryan Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana

Oral Abstract: Maternal-Child Health and Treatment of Malignancies

"Lenacapavir Pharmacokinetics, Safety, and Efficacy in Adolescents and Adults in PURPOSE 1" by Katherine Gill Desmond Tutu HIV Foundation, Cape Town, South Africa

Oral Abstract: Maternal-Child Health and Treatment of Malignancies

"Questions and Answers Part 1" by

Oral Abstract: Maternal-Child Health and Treatment of Malignancies

"Introduction of Speakers Part 2" by

Oral Abstract: Maternal-Child Health and Treatment of Malignancies

"Assessing IIT and Mortality Among CLHIV <15 yo in PEPFAR-Supported Countries, FY21 - FY24" by Michelle Yang US Department of State, Washington, DC, USA

Oral Abstract: Maternal-Child Health and Treatment of Malignancies

"Multidose PK/Safety of Dolutegravir Dispersible Tablets & Oral Films in Neonates: PETITE-DTG Study" by Adrie Bekker Stellenbosch University, Cape Town, South Africa

Oral Abstract: Maternal-Child Health and Treatment of Malignancies

"Genotypic Resistance in the African Paediatric CHAPAS-4 Trial of Second-Line Antiretroviral Therapy" by Alasdair Bamford Great Ormond Street NHS Foundation Trust, London, UK

Oral Abstract: Maternal-Child Health and Treatment of Malignancies

"Abemaciclib, a CDK4/6 Inhibitor, in HIV-Associated and HIV-Negative Kaposi Sarcoma" by Jose R. Mercado-Matos National Cancer Institute, Bethesda, MD, USA

Oral Abstract: Maternal-Child Health and Treatment of Malignancies

"Differences in Treatment and Overall Survival in People With and Without HIV and Oropharynx Cancer" by Elizabeth Chiao University of Texas MD Anderson Cancer Center, Houston, TX, USA

Oral Abstract: Maternal-Child Health and Treatment of Malignancies

"Questions and Answers Part 2" by

Oral Abstract: The Coinfections: Hepatitis and TB

"Introduction of Speakers Part 1" by

Oral Abstract: The Coinfections: Hepatitis and TB

"Trends in Hepatitis C Virus (HCV) Infection Incidence Among PWH Engaged in Care in the US: 1995-2023" by Yotam Arens Weill Cornell Medicine, New York, NY, USA

Oral Abstract: The Coinfections: Hepatitis and TB

"HIV Decreases Both Hepatitis B Antibody Titer and Neutralization After Spontaneous HBV Control" by Chloe Thio The Johns Hopkins University School of Medicine, Baltimore, MD, USA

Oral Abstract: The Coinfections: Hepatitis and TB

"HBV Care Continuum and Associated Factors in Rwanda: A Population-Based Study From 2016-2023" by Jean Damascene Makuza University of British Columbia, Vancouver, Canada

Oral Abstract: The Coinfections: Hepatitis and TB

"Intrahepatic Transcriptomics in HBV-HIV Co-Infection Uncover Host Responses to HBV Transcription" by Che-Min Lo The Johns Hopkins University School of Medicine, Baltimore, MD, USA

Oral Abstract: The Coinfections: Hepatitis and TB

"Questions and Answers Part 1" by

Oral Abstract: The Coinfections: Hepatitis and TB

"Introduction of Speakers Part 2" by

Oral Abstract: The Coinfections: Hepatitis and TB

"Highly Durable Seroprotection With HepB-CpG Vaccine in People With HIV (PWH): ACTG A5379 (BEeHIVe)" by Kristen Marks Weill Cornell Medicine, New York, NY, USA

Oral Abstract: The Coinfections: Hepatitis and TB

"Epigenetic Age Predictors of Semaglutide-Related Liver Fat Changes in People With HIV" by Alina Pang Weill Cornell Medicine, New York, NY, USA

Oral Abstract: The Coinfections: Hepatitis and TB

"Supplemental High-Dose Rifampicin and Levofloxacin for Inpatients With Disseminated HIV-TB" by Graeme Meintjes University of Cape Town, Cape Town, South Africa

Oral Abstract: The Coinfections: Hepatitis and TB

"Casual Contact in Community Settings Explains Majority of TB Transmission in South Africa" by Neel R. Gandhi Emory University, Atlanta, GA, USA

Oral Abstract: The Coinfections: Hepatitis and TB

"DOLPHIN-Moms: Pharmacokinetics of Dolutegravir and HIV Viral Suppression With 1HP or 3HP in Pregnancy" by Jyoti Mathad Weill Cornell Medicine, New York, NY, USA

Oral Abstract: The Coinfections: Hepatitis and TB

"Questions and Answers Part 2" by

Oral Abstract: Antivirals For HIV, MPXV, and SARS-CoV-2: New Drug Strategies and Resistance

"Introduction of Speakers Part 1" by

Oral Abstract: Antivirals For HIV, MPXV, and SARS-CoV-2: New Drug Strategies and Resistance

"Efficacy and Safety of Lenacapavir, Teropavimab, and Zinlirvimab: Phase II Week 26 Primary Outcome" by Onyema Ogbuagu Yale University, New Haven, CT, USA

Oral Abstract: Antivirals For HIV, MPXV, and SARS-CoV-2: New Drug Strategies and Resistance

"Proof-of-Concept Trial of VH4524184 (VH-184), a Third-Generation Integrase Strand Transfer Inhibitor" by Luise Rogg ViiV Healthcare, Durham, NC, USA

Oral Abstract: Antivirals For HIV, MPXV, and SARS-CoV-2: New Drug Strategies and Resistance

"Proof-of-Concept Trial of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor" by Paul Benn ViiV Healthcare, Brentford, UK

Oral Abstract: Antivirals For HIV, MPXV, and SARS-CoV-2: New Drug Strategies and Resistance

"Pharmacokinetics and Safety of Once-Yearly Formulations of Lenacapavir" by Renu Singh Gilead Sciences, Inc, Foster City, CA, USA

Oral Abstract: Antivirals For HIV, MPXV, and SARS-CoV-2: New Drug Strategies and Resistance

"Questions and Answers Part 1" by

Oral Abstract: Antivirals For HIV, MPXV, and SARS-CoV-2: New Drug Strategies and Resistance

"Introduction of Speakers Part 2" by

Oral Abstract: Antivirals For HIV, MPXV, and SARS-CoV-2: New Drug Strategies and Resistance

"Elucidating the Mechanism by Which Nucleocapsid Mutations Confer Resistance to InSTIs" by Yuta Hikichi National Cancer Institute at Frederick, Frederick, MD, USA

Oral Abstract: Antivirals For HIV, MPXV, and SARS-CoV-2: New Drug Strategies and Resistance

"Selection of Nucleocapsid Mutations With Virologic Failure of Tenofovir/Lamivudine/Dolutegravir" by Kerri J. Penrose University of Pittsburgh, Pittsburgh, PA, USA

Oral Abstract: Antivirals For HIV, MPXV, and SARS-CoV-2: New Drug Strategies and Resistance

"Optimizing On-Demand Tenofovir Disoproxil Fumarate/Emtricitabine Dosing in Women for HIV Prevention" by Mackenzie Cottrell University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Oral Abstract: Antivirals For HIV, MPXV, and SARS-CoV-2: New Drug Strategies and Resistance

"Safety and Antiviral Efficacy of a Broad-Spectrum siRNA SNS812 Targeting SARS-CoV-2: Phase II Trial" by Shey-Ying Chen National Taiwan University Hospital, Taipei, Taiwan

Oral Abstract: Antivirals For HIV, MPXV, and SARS-CoV-2: New Drug Strategies and Resistance

"Host and Disease Factors Were Not Associated With Mpox Resolution in Participants Receiving Tpoxx" by William A. Fischer II University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Oral Abstract: Antivirals For HIV, MPXV, and SARS-CoV-2: New Drug Strategies and Resistance

"Questions and Answers Part 2" by

Oral Abstract: Immunology and Vaccines

"Introduction of Speakers Part 1" by

Oral Abstract: Immunology and Vaccines

"Profiling Therapeutic Vaccine-Driven HIV-Specific CD8 T Cells With Single-Cell TCR Sequencing Assays" by Rafael Tiburcio University of California San Francisco, San Francisco, CA, USA

Oral Abstract: Immunology and Vaccines

"Efficacy of Bivalent Versus Monovalent COVID-19 Vaccines Among People With HIV, Ubuntu Trial, 2022-24" by Sufia Dadabhai The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

Oral Abstract: Immunology and Vaccines

"T-Cell Responses Induced by GS-1966+GS-1144 Vaccines in Virally Suppressed People With HIV" by Devi Sengupta Gilead Sciences, Inc, Foster City, CA, USA

Oral Abstract: Immunology and Vaccines

"Lymph Node HIV-Specific CD8 T Cells of HIV Controllers Harbour a Specific Transcriptomic Signature" by Andrea Mastrangelo Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Oral Abstract: Immunology and Vaccines

"Questions and Answers Part 1" by

Oral Abstract: Immunology and Vaccines

"Introduction of Speakers Part 2" by

Oral Abstract: Immunology and Vaccines

"HIV-Specific CD8+ T Cell Stemness Predicts Postintervention Control of Viremia" by David R. Collins Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA

Oral Abstract: Immunology and Vaccines

"Immunologic Impact of Short-Term BCL2 Inhibition at ART Initiation on SIV-Infected Rhesus Macaques" by Tomas Raul Wiche Salinas Emory University, Atlanta, GA, USA

Oral Abstract: Immunology and Vaccines

"Bispecific Antibody VRC07/PGT121 Protects Against High-Dose Intravenous SHIV-BG505 Challenge" by Matthew S. Parsons Armed Forces Research Institute of Medical Sciences in Bangkok, Bangkok, Thailand

Oral Abstract: Immunology and Vaccines

"Time-to-Rebound Measurements in ATI Trials With bNAb Intervention Are Confounded by Autologous NAbs" by Mauro Garcia The Johns Hopkins University School of Medicine, Baltimore, MD, USA

Oral Abstract: Immunology and Vaccines

"Broad V2-Apex bNAb Activity in HIV-1 Through a Novel, K169-Independent bNAb" by Maria C. Hesselman University of Zurich, Zurich, Switzerland

Oral Abstract: Immunology and Vaccines

"Questions and Answers Part 2" by

Oral Abstract: New Frontiers in STI Prevention

"Introduction of Speakers Part 1" by

Oral Abstract: New Frontiers in STI Prevention

"Missed Opportunities for Syphilis Diagnosis With Targeted Compared to Universal Screening" by Kimberly A. Stanford University of Chicago Medical Center, Chicago, IL, USA

Oral Abstract: New Frontiers in STI Prevention

"Higher Odds of Congenital Syphilis With 9- vs 7-Day Prenatal Treatment Intervals for Late Syphilis" by Kelly A. Johnson University of California San Francisco, San Francisco, CA, USA

Oral Abstract: New Frontiers in STI Prevention

"DoxyPEP Eligibility, Use, and Potential for STI Reduction in a Large HIV Cohort in Washington, DC" by Amanda D. Castel The George Washington University, Washington, DC, USA

Oral Abstract: New Frontiers in STI Prevention

"High Sustained Effectiveness of Doxycycline PEP for STI Prevention After Clinical Implementation" by Hyman Scott San Francisco Department of Public Health, San Francisco, CA, USA

Oral Abstract: New Frontiers in STI Prevention

"Questions and Answers Part 1" by

Oral Abstract: New Frontiers in STI Prevention

"Introduction of Speakers Part 2" by

Oral Abstract: New Frontiers in STI Prevention

"The Doxy-PEP Continuum Among Patients Receiving Care at a Sexual Health Clinic in San Francisco" by Michael P. Barry San Francisco AIDS Foundation, San Francisco, CA, USA

Oral Abstract: New Frontiers in STI Prevention

"Global Modelling Analysis: Impact of Improved HPV Vaccination on Noncervical Cancers in PLWHIV" by Namwa Wongkalasin Imperial College London, London, UK

Oral Abstract: New Frontiers in STI Prevention

"Impact of Urine TFV Testing on PrEP Adherence in South African Pregnant and Postpartum Women: An RCT" by Dvora L. Joseph Davey University of California Los Angeles, Los Angeles, CA, USA

Oral Abstract: New Frontiers in STI Prevention

"Questions and Answers Part 2" by

Oral Abstract: What Do Viruses Do, and How Do They Do It?

"Introduction of Speakers Part 1" by

Oral Abstract: What Do Viruses Do, and How Do They Do It?

"Replication-Competent HIV-Infected Cells Have Deoxyuracil-Containing Proviruses" by Rodrigo Matus Nicodemos Vaccine Research Center, Bethesda, MD, USA

Oral Abstract: What Do Viruses Do, and How Do They Do It?

"Gag-Mediated Control Over CARD8 Activation During HIV-1 Assembly" by Ivy K. Hughes Boston University, Boston, MA, USA

Oral Abstract: What Do Viruses Do, and How Do They Do It?

"Direct Visualization of HIV-1 Nuclear Import and Its Interplay With the Nuclear Pore" by Yao Shen University of Oxford, Oxford, UK

Oral Abstract: What Do Viruses Do, and How Do They Do It?

"Visualizing the Cell Biology of HIV Latency and Reactivation" by Jonathan Karn Case Western Reserve University, Cleveland, OH, USA

Oral Abstract: What Do Viruses Do, and How Do They Do It?

"Questions and Answers Part 1" by

Oral Abstract: What Do Viruses Do, and How Do They Do It?

"Introduction of Speakers Part 2" by

Oral Abstract: What Do Viruses Do, and How Do They Do It?

"Single-Cell Spatial Profiling Identified Intact HIV+ Cells in Lymph Nodes" by Amare Eshetu Yale University, New Haven, CT, USA

Oral Abstract: What Do Viruses Do, and How Do They Do It?

"Lenacapavir Directs Specific Proteasome-Mediated Degradation of Gag Proteins in HIV-Infected Cells" by Clayton Faua University Hospital of Strasbourg, Strasbourg, France

Oral Abstract: What Do Viruses Do, and How Do They Do It?

"RhCMV Expands CCR5 Memory CD4 T Cells and Increases Acute-Phase Seeding of SIV DNA in the Gut Mucosa" by Chrysostomos Perdios Tulane National Primate Research Center, Covington, LA, USA

Oral Abstract: What Do Viruses Do, and How Do They Do It?

"Differential Replication, Innate Immune Control, and Virulence of Global and Endemic Clade II MPXV" by Rebecca P. Sumner University Surrey, Guildford, UK

Oral Abstract: What Do Viruses Do, and How Do They Do It?

"Nef Modulates Actin to Prevent Postintegration Sensing of HIV-1" by Alexandre Laliberté Ulm University Medical Center, Ulm, Germany

Oral Abstract: What Do Viruses Do, and How Do They Do It?

"Questions and Answers Part 2" by

Oral Abstract: Cardiometabolic Complications and Aging: The Clock Is Ticking

"Introduction of Speakers Part 1" by

Oral Abstract: Cardiometabolic Complications and Aging: The Clock Is Ticking

"Major Improvement in Age-Related Health Outcomes in People Living With HIV: An 18-Year Cohort Study" by Alejandro Garcia Hospital Ramón y Cajal, Madrid, Spain

Oral Abstract: Cardiometabolic Complications and Aging: The Clock Is Ticking

"Early vs Deferred HIV Therapy and Cardiovascular Disease in People With HIV: The START Study" by Nila J. Dharan University of New South Wales Sydney, Sydney, Australia

Oral Abstract: Cardiometabolic Complications and Aging: The Clock Is Ticking

"Epidemiology of Coronary Atherosclerosis Among People Living With HIV in Uganda" by Mark J. Siedner Massachusetts General Hospital, Boston, MA, USA

Oral Abstract: Cardiometabolic Complications and Aging: The Clock Is Ticking

"Plaque, Inflammation, Subclinical Myocardial Injury, and MACE in the REPRIEVE Mechanistic Substudy" by Steven Grinspoon Massachusetts General Hospital, Boston, MA, USA

Oral Abstract: Cardiometabolic Complications and Aging: The Clock Is Ticking

"Questions and Answers Part 1" by

Oral Abstract: Cardiometabolic Complications and Aging: The Clock Is Ticking

"Introduction of Speakers Part 2" by

Oral Abstract: Cardiometabolic Complications and Aging: The Clock Is Ticking

"Frailty Is Associated With Higher MACE Incidence but Does Not Appear to Modify Pitavastatin Effects" by Kristine M. Erlandson University of Colorado Anschutz Medical Campus, Aurora, CO, USA

Oral Abstract: Cardiometabolic Complications and Aging: The Clock Is Ticking

"Prognostic Value of Epigenetic Age Acceleration in People With Well-Controlled HIV Infection" by Patricia Martínez-Martín La Paz University Hospital, Madrid, Spain

Oral Abstract: Cardiometabolic Complications and Aging: The Clock Is Ticking

"Semaglutide Stabilizes Epigenetic Aging in People With HIV-Associated Lipohypertrophy" by Michael J. Corley Weill Cornell Medicine, New York, NY, USA

Oral Abstract: Cardiometabolic Complications and Aging: The Clock Is Ticking

"Letermovir for CMV Suppression Improves Immunologic and Functional Aging Outcomes in Treated HIV" by Sara Gianella Weibel University of California San Diego, La Jolla, CA, USA

Oral Abstract: Cardiometabolic Complications and Aging: The Clock Is Ticking

"Questions and Answers Part 2" by

Oral Abstract: Expanding the Prevention Toolbox

"Introduction of Speakers Part 1" by

Oral Abstract: Expanding the Prevention Toolbox

"Long-Acting Cabotegravir PrEP Uptake and Persistence in a Large US Healthcare System" by Michael Traeger Harvard Pilgrim Health Care Institute, Boston, MA, USA

Oral Abstract: Expanding the Prevention Toolbox

"ImPrEP CAB Brasil: Enhancing PrEP Coverage With CAB-LA in Young Key Populations" by Beatriz Grinsztejn Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil

Oral Abstract: Expanding the Prevention Toolbox

"Estimation of Prevention-Effective CAB-LA Concentrations Among MSM/TGW in HPTN 083" by Brett S. Hanscom Fred Hutchinson Cancer Center, Seattle, WA, USA

Oral Abstract: Expanding the Prevention Toolbox

"Adherence to F/TAF in Cisgender Women Prevents HIV With Low Risk of Resistance or Diagnostic Delay" by Flavia M. Kiweewa Makerere University–Johns Hopkins University Research Collaboration, Kampala, Uganda

Oral Abstract: Expanding the Prevention Toolbox

"Questions and Answers Part 1" by

Oral Abstract: Expanding the Prevention Toolbox

"Introduction of Speakers Part 2" by

Oral Abstract: Expanding the Prevention Toolbox

"Performance of HIV RNA Screening in the Context of Long-Acting Injectable Cabotegravir in HPTN 084" by Sinead Delany-Moretlwe University of the Witwatersrand, Johannesburg, South Africa

Oral Abstract: Expanding the Prevention Toolbox

"PILLAR Month 12 Clinical Results: Zero HIV Acquisition and High Persistence With CAB LA for PrEP" by Taimur Khan Fenway Health, Boston, MA, USA

Oral Abstract: Expanding the Prevention Toolbox

"Response to HIV Treatment After Long-Acting Cabotegravir Preexposure Prophylaxis in HPTN 083" by Raphael J. Landovitz University of California Los Angeles, Los Angeles, CA, USA

Oral Abstract: Expanding the Prevention Toolbox

"An Injectable Multipurpose Implant With CAB and MPA for Long-Acting HIV Prevention and Contraception" by S. Rahima Benhabbour University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Oral Abstract: Expanding the Prevention Toolbox

"Questions and Answers Part 2" by

Oral Abstract: Gaps and Solutions in the HIV Response

"Introduction of Speakers Part 1" by

Oral Abstract: Gaps and Solutions in the HIV Response

"Preliminary Efficacy for HPTN 094: 26-Week RCT of Integrated Strategies for People Who Inject Drugs" by Steve Shoptaw University of California Los Angeles, Los Angeles, CA, USA

Oral Abstract: Gaps and Solutions in the HIV Response

"Most With HIV Viremia Are Not in Care Despite High ART Coverage: A Population-Based Study in Uganda" by Silas Odiya Rakai Health Sciences Program, Kalisizo, Uganda

Oral Abstract: Gaps and Solutions in the HIV Response

"Low-Cost Counseling Achieves Positive Outcomes for Malawi Men Disengaged From Care: Randomized Trial" by Kathryn L. Dovel University of California Los Angeles, Los Angeles, CA, USA

Oral Abstract: Gaps and Solutions in the HIV Response

"Clinic Switching and Elevated HIV Viral Load in 6 African Countries: A Population-Based Study" by Joseph G. Rosen Brown University, Providence, RI, USA

Oral Abstract: Gaps and Solutions in the HIV Response

"Questions and Answers Part 1" by

Oral Abstract: Gaps and Solutions in the HIV Response

"Introduction of Speakers Part 2" by

Oral Abstract: Gaps and Solutions in the HIV Response

"How Do Repeated Financial Incentives Affect HIV Care-Seeking Behaviors Over Time?" by Solis Winters University of California Berkeley, Berkeley, CA, USA

Oral Abstract: Gaps and Solutions in the HIV Response

"Effect of a Person-Centered Care Intervention on Reengagement After Care Interruptions in Zambia" by Aaloke Mody Washington University in St Louis, St Louis, MO, USA

Oral Abstract: Gaps and Solutions in the HIV Response

"Systems Analysis and Improvement Approach to Optimize Hypertension Care for People Living With HIV" by Sarah Gimbel University of Washington, Seattle, WA, USA

Oral Abstract: Gaps and Solutions in the HIV Response

"SEARCH Integrated HIV/Hypertension Community Health Worker-Led Intervention in Rural East Africa" by Matt Hickey University of California San Francisco, San Francisco, CA, USA

Oral Abstract: Gaps and Solutions in the HIV Response

"Questions and Answers Part 2" by

Oral Abstract: Viruses Always On My Mind: Viral Neuropathogenesis From Acute HIV to SARS-CoV-2

"Introduction of Speakers Part 1" by

Oral Abstract: Viruses Always On My Mind: Viral Neuropathogenesis From Acute HIV to SARS-CoV-2

"Brain Volume Normalization After 96 Weeks of ART Started During Acute HIV Infection" by Robert Paul University of Missouri St Louis, St Louis, MO, USA

Oral Abstract: Viruses Always On My Mind: Viral Neuropathogenesis From Acute HIV to SARS-CoV-2

"Spinal Cord as a Distinct Site of HIV Persistence and Dispersal in the Brain" by Mattia Trunfio University of California San Diego, La Jolla, CA, USA

Oral Abstract: Viruses Always On My Mind: Viral Neuropathogenesis From Acute HIV to SARS-CoV-2

"Longitudinal Persistence of HIV DNA in CSF Over 4 Years Despite Up to 20 Years of ART" by Joshua C. Cyktor University of Pittsburgh, Pittsburgh, PA, USA

Oral Abstract: Viruses Always On My Mind: Viral Neuropathogenesis From Acute HIV to SARS-CoV-2

"Single-Nuclei Multiome Analysis of CSF Cells Reveals Dendritic Cell Dysregulation Despite ART" by Shelli Farhadian Yale University, New Haven, CT, USA

Oral Abstract: Viruses Always On My Mind: Viral Neuropathogenesis From Acute HIV to SARS-CoV-2

"Questions and Answers Part 1" by

Oral Abstract: Viruses Always On My Mind: Viral Neuropathogenesis From Acute HIV to SARS-CoV-2

"Introduction of Speakers Part 2" by

Oral Abstract: Viruses Always On My Mind: Viral Neuropathogenesis From Acute HIV to SARS-CoV-2

"Plasma Phosphorylated Tau 217 and Cognitive Decline in Older Thai People With HIV" by Akarin Hiransuthikul Chulalongkorn University, Bangkok, Thailand

Oral Abstract: Viruses Always On My Mind: Viral Neuropathogenesis From Acute HIV to SARS-CoV-2

"Semaglutide Improves Cognitive Function in HIV, Effect Mediated by Decrease in Inflammation" by Ornina Atieh Case Western Reserve University, Cleveland, OH, USA

Oral Abstract: Viruses Always On My Mind: Viral Neuropathogenesis From Acute HIV to SARS-CoV-2

"Brain Gray and White Matter Alterations in Cognitive Long COVID" by Lindsay S. McAlpine Yale University, New Haven, CT, USA

Oral Abstract: Viruses Always On My Mind: Viral Neuropathogenesis From Acute HIV to SARS-CoV-2

"Structural Brain Volumes Decrease After SARS-CoV-2 Infection Among People With HIV" by Jacob Bolzenius University of Missouri St Louis, St Louis, MO, USA

Oral Abstract: Viruses Always On My Mind: Viral Neuropathogenesis From Acute HIV to SARS-CoV-2

"Questions and Answers Part 2" by

Oral Abstract: Late-Breaking Antiviral Therapy: It Doesn’t Get Any Hotter Than This!

"(Introduction of Speakers)" by

Oral Abstract: Late-Breaking Antiviral Therapy: It Doesn’t Get Any Hotter Than This!

"Ensitrelvir to Prevent COVID-19 in Households: SCORPIO-PEP Phase III Placebo-Controlled Trial Results" by Frederick G. Hayden University of Virginia, Charlottesville, VA, USA

Oral Abstract: Late-Breaking Antiviral Therapy: It Doesn’t Get Any Hotter Than This!

"Tecovirimat Is Safe but Not Efficacious in People With Clade II Mpox" by Timothy Wilkin University of California San Diego, La Jolla, CA, USA

Oral Abstract: Late-Breaking Antiviral Therapy: It Doesn’t Get Any Hotter Than This!

"Randomized Trial of Long-Acting Cabotegravir and Rilpivirine in Africa (CARES): Week 96 Results" by Cissy Kityo Joint Clinical Research Centre, Kampala, Uganda

Oral Abstract: Late-Breaking Antiviral Therapy: It Doesn’t Get Any Hotter Than This!

"VH3810109 (N6LS) Efficacy and Safety in Adults Who Are Virologically Suppressed: The EMBRACE Study" by Babafemi Taiwo ViiV Healthcare, Durham, NC, USA

Oral Abstract: Late-Breaking Antiviral Therapy: It Doesn’t Get Any Hotter Than This!

"Switch to DOR/ISL (100/0.25 mg) QD From BIC/FTC/TAF: A Blinded Phase III Study in Adults With HIV-1" by Amy E. Colson Community Resource Initiative, Boston, MA, USA

Oral Abstract: Late-Breaking Antiviral Therapy: It Doesn’t Get Any Hotter Than This!

"Switch to DOR/ISL (100/0.25 mg) QD From Oral ART: An Open-Label Phase III Study in Adults With HIV-1" by Chloe Orkin Queen Mary University of London, London, UK

Oral Abstract: Late-Breaking Antiviral Therapy: It Doesn’t Get Any Hotter Than This!

"Questions and Answers" by